

Singapore-based AIM Biotech launches new system to model human disease

04 October 2022 | News

Combining Organoids, Perfusable Vasculature and Immune-Competence



Singapore and US-based startup AIM Biotech has announced the launch of the organiX System, a lab tool to closely model human disease by adding vascularization and immune competence to organoids, spheroids and tumour biopsies.

Adding vascularization and immune cells to a disease model creates a more defined and tunable microenvironment to more closely emulate the complexity of human physiology. This is all packaged together in an easy-to-use tool, designed around a universal plate format, so labs and researchers can more easily study diseases, more accurately predict success of investigational treatments and better predict optimal patient therapies.

The organiX platform is specifically designed to host human tissue biopsies or organoids of up to 2 mm in diameter. These tissue models are increasingly adopted by clinicians and biotech organizations, and have the potential to revolutionize the assessment of conventional and experimental approaches to cancer treatment. The promise is for researchers to test and co-culture cells in a more physiologically meaningful arrangement to better predict human response and compliment genetic data.

AIM Biotech has acquired the worldwide exclusive license to this technology from A*STAR Singapore's Institute of Molecular and Cell Biology (IMCB).